“Lemongrass” and its applications for the treatment of hypertension
Infectious Diseases and Herbal Medicine · 2021
DOI: 10.4081/idhm.2021.172 ↗Kurz gefasst
Fachartikel in der Zeitschrift Infectious Diseases and Herbal Medicine, 2021. Verfasst von Siukan Law und 1 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Hypertension (high blood pressure) is the pre-symptom of cardiovascular disease. The number of people living with hypertension has doubled to 1.28 billion and proportionally increased until today. This is a long-term disease and requires continuous monitoring. A traditional Chinese herbal, “Lemongrass”, might be a good choice for the mainstay of hypertension. Some library search engines are used, such as SCI/SCIE, PubMed, and Scopus, within ten to twenty years, from 1999-2020. The searched keywords and phrases are “lemongrass”, “formulation”, “traditional Chinese medicine”, “hydrogel”, “hypertension”, “lemongrass + tea formulation”, “lemongrass + hydrogel”, “Lemongrass + Hypertension”, “Lemongrass + traditional Chinese medicine” etc. This minireview discusses the background of hypertension, lemongrass, research progress, mechanism, lemongrass tea formulations, lemongrass with Traditional Chinese Medicine (TCM) formulations, and the lemongrass hydrogel application in the treatment of hypertension.
Zitieren
APA
Law, S., & Lo, C. (2021). “Lemongrass” and its applications for the treatment of hypertension. Infectious Diseases and Herbal Medicine. https://doi.org/10.4081/idhm.2021.172
Vancouver
Law S, Lo C. “Lemongrass” and its applications for the treatment of hypertension. Infectious Diseases and Herbal Medicine. 2021. doi:10.4081/idhm.2021.172
BibTeX
@article{Law2021,
author = {Law, Siukan and Lo, Chuiman},
title = {“Lemongrass” and its applications for the treatment of hypertension},
journal = {Infectious Diseases and Herbal Medicine},
year = {2021},
doi = {10.4081/idhm.2021.172}
}
EUVIMED